A racemic mixture of EPA derivatives, active against P. acnes and S. aureus (MICs = 128 and 512 mg/L, respectively), inhibits fMLP-induced aggregation of isolated rat neutrophils (IC50 = 4.7 µM), BALF levels are increased in patients with allergic asthma or COVID-19
